                               SEQUENCE LISTING

<110> NOVARTIS AG
 
<120> METHODS AND COMPOSITIONS FOR DIAGNOSING, TREATING, AND MONITORING
      TREATMENT OF SHANK3 DEFICIENCY ASSOCIATED DISORDERS

<130> PAT056917-WO-PCT

<140>
<141>

<150> 62/171,264
<151> 2015-06-05

<160> 13    

<170> PatentIn version 3.5

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 1
ccacgtcact cacaagtttc t                                                 21


<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 2
ggtttggagt ctggactaag c                                                 21


<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 3
ggaagtcacc agaggacaag a                                                 21


<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 4
aacttacgct gagtacttcg a                                                 21


<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 5
gcatcatctt tgagtactac g                                                 21


<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 6
cttctcggat gatcagaaag a                                                 21


<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 7
gaatatgtgg aatagtgtaa a                                                 21


<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 8
gaatagtgta aatatgacag a                                                 21


<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 9
acatgtatat actactattt a                                                 21


<210> 10
<211> 9
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      wild type human, mouse or rat B56beta (PPP2r5b) sequence"

<400> 10
Arg Ser His Ser Ser Ser Gln Phe Arg 
1               5                   


<210> 11
<211> 26
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      wild type human, mouse or rat B56beta sequence"

<400> 11
Gly Phe Ser Arg Arg Ser Leu Arg Arg Ala Arg Pro Arg Arg Ser His 
1               5                   10                  15      


Ser Ser Ser Gln Phe Arg Tyr Gln Ser Asn 
            20                  25      


<210> 12
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 12
Gly Phe Ala Arg Arg Ala Leu Arg Arg Ala Arg Pro Arg Arg Ala His 
1               5                   10                  15      


Ala Ala Ala Gln Phe Arg Tyr Gln Ser Asn 
            20                  25      


<210> 13
<211> 11
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      CLK family LAMMER kinase peptide"

<400> 13
Glu His Leu Ala Met Met Glu Arg Ile Leu Gly 
1               5                   10      


